Member Info for Parpaing

highlight the link , right click, "open link in new tab". Include the ' ,d.bGQ 'at the end which is not in blue.

The most interesting information for investors in XBIO can be found here (PDF): http://www.google.co.uk/url?sa=t&rct=j&q=&esrc=s&source=web&cd=1&ved=0CCEQFjAA&url=http%3A%2F%2Fwww.acadpharm.org%2Fdos_public%2FGabibov_-_LAcademie_de_Pharmacie_02_04_14.pdf&ei=pUz_VIvQLYr1UNO2gdgH&usg=AFQjCNGehcxjlEMRbNlkzlNRLh751qRq4Q&bvm=bv.87611401,d.bGQ I urge you all to read it. Because you will sympathize with Scott's frustrations. The XBIO products are blockbusters - if we can get them to market ASAP.

The info I have found is that the trial for EPO is ongoing in Russia and the end date is estimated to be 31.12.2016. The start date was 15.02.2013. SynBio is named as the drug developer for EPOXXXX. the trial is an open, controlled, multicentre, randomized clinical trial in studying the efficiency, safety and tolerance of EPOXXXX in correcting anemia and supporting hemoglobin in EPO-naive patients with chronic kidney disease who are not on dialysis. 15- patients taking part. This trial is in comparison with ARANESP. Other companies (Astro Zenca, Roche) are trialling EPO -based drugs in Russia. FibroGen with Astrazeneca are also in the recruiting stage for a trial with their FG-4592 drug that finishes in 2017. they are in phase 3 and estimated study finish date is June 2017. It is evident that these trials take time. Now is the time to concentrate on getting NASDACKED.

Yes, the only thing I don't understand (at the moment) is that Synbio doesn't seem to exist as a company as it was taken over by Pharmsyntez. I will be doing some research later next week to get the details and information on the trials in Russia. My limited research shows that SynBio does not have any authorization in Russia to carry out trials. I will find out who the authorized company is conducting the trials and trial details to date. Scott stated that he has difficulty in getting information from Russia. I will be carrying out my research at the the Ministry of Health level in Russia who will give me the info about the trials and see if I can help Scott. Meanwhile, a message for LordSnooty, Lidl is having an special offer on Fine Calvados at 14.9 euros in France.

BIOM awarded government grant for the lignin product. Real enough for you?

People who are pessimistic are more often right than wrong. They certainly do not belong within the ranks of stalwart entrepreneurs and brave investors. They can, however, find a warm welcome with their companions on BPC.

Life Size Media is getting BIOM's message out there - which is more positive than the posts on this board. http://www.life-size-media.com/blog/2014/life-size-in-action-3d-printing/

http://life-size-media.com/campaign_lignin.php

http://www.biomebioplastics.com/biome-bioplastics-serves-taste-of-industrial-biotechnology-to-minister-for-life-sciences/

has nothing to say. Just waiting for increased revenue figures. Parpaing is indeed French for 'breeze block' and you need to have a skin of similar thickness to put up with the shenanigans of AIM. This share is no different to anything else on AIM or the LSE for that matter. There is always an excuse for the MMs to mark down everything - Ukraine, ISIS, oil etc. the news is always the same, just the names change. BIOM is a company that is trying very hard to increase their product lines. The 3D printing filament is a really good product and should add to BIOM's fortunes. Next year, Rodney, next year we'll be millionaires!

Good news - so that means the SP will be.....

Excellent ! Love it - can't stop laughing.

Scott said that the NASDAQ problem is "fixable". he also said that information coming from Russia was slow. Here is part of the content of my email to Scott: "We do not quite understand the problem you have about getting information on the Russian clinical trials. The clinical trials administration is very straightforward and based on official procedures developed by the Russian Ministry of Health. SynBio has to submit documentation to the MoH for permission to run the trials. The MoH and the Ethical Committee will provide the decision based on official procedures. SynBio as with any CRO has to provide periodic updates to the Trials Sponsor and the MoH, which includes, as a minimum, intermediate reports and final reports. The CRO and the clinical trials site have to, by law, inform the Sponsor promptly, (within 24 -48 hours) of any SAE, AE, and SUSAR. The Sponsor has an ongoing control over any clinical trial and access to any information concerning the trial. The Sponsor can also see any confidential patient records." We just need Mr. Leeson to keep us smiling for the next three months and somebody in the US to educate institutions and PIs on the merits of XBIO. After all, XBIO is the next Microsoft, Apple etc.

See: http://www.biometechnologiesplc.com/news/54/biome_technologies_releases_pre_close_statement.php

is that my other half is saying "I told you so" and holidays, new car, retirement has now been postponed until we NASDACKED !

The Russians are well regulated, as I informed Scott yesterday via email. The clinical trials administration is very straightforward and based on official procedures developed by the Russian Ministry of Health. SynBio has to submit documentation to the MoH for permission to run the trials. The MoH and the Ethical Committee will provide the decision based on official procedures. SynBio as with any CRO has to provide periodic updates to the Trials Sponsor and the MoH, which includes, as a minimum, intermediate reports and final reports. The CRO and the clinical trials site have to, by law, inform the Sponsor promptly, (within 24 -48 hours) of any SAE, AE, and SUSAR. The Sponsor has an ongoing control over any clinical trial and access to any information concerning the trial. The Sponsor can also see any confidential patient records. If successful, the clinical trials will be reported ASAP. If they are unsuccessful, the Sponsor may wish to hold the information back or suspend the trials to suit their business plans.

Regarding Scott's mention about institutional investors, what does it matter if one investor buys a million shares or 1,000 PIs buy 1,000 shares each? Its then a marketing problem, not an institutional problem.

Meanwhile back to XBIO. Scott should concentrate on fixing the major problem of the NASDAQ listing. He said yesterday that it is ‘fixable’. I hope so. The Davos conference is underway and the outcome will be the lifting of sanctions and the US will have to bite its tongue. Moscow has a fiscal surplus, barely any government debt, lots of sovereign wealth stashed away and can last longer than the West in this stand-off.

Enslin has said it all really. Until the phase III trial has concluded in Russia for Erepoxen (and the same for India and Australia) there is nothing to party about. Both Xenetic and SynBio are really slack in updating their websites which does not help new investors in evaluating the company or its products. If their websites were a bit more enthusiastic and updated at least every month we might see some enthusiasm from the market. However, Scott mentioned that institutional investors prefer to deal in tens of thousands of shares rather than in thousands on the OTC. My take is that the current sanctions are somewhat interfering in the process. Russia is laying off medical staff in thousands and closing hospitals. People are having to travel further for medical help. Clinical trials are on the back burner as doctors are worried that their jobs are under threat. All because the US is putting pressure on its European ‘friends’ to put the squeeze on M Putin. Thanks to this playground Obama v Putin tiff, Europe is directly affected and feeling the pinch. Obama is not admired abroad and Putin is a successful national leader with the support of his people. Russia does not want to get involved in the Ukraine and is simply protecting its borders against the criminal element in Ukraine that is pushing for power. The last thing Putin wants is a Ukrainian chocolate king banging on its door for financial help. The IMF is propping up the Ukraine government which is in financial meltdown. My personal belief is that the US should get their own house in order before getting involved in other squabbles. The prep school sanctions have hurt Europe much more than Russia and Russia can withstand a lot more hardship than Europe. Angela Merkel and M. Hollande are desperate to stop the sanctions as France has two warships waiting to be delivered to Russia. These ships are no good to anyone else because every plaque, text and description on these boats are in Russian. The manuals are in French and Russian etc. With the late delivery penalties accruing, Russia would rather have the money than the ships. French food suppliers are pressurizing the government to stop the sanctions as they have lost, in some cases, their largest customer. Meanwhile the Russian attitude is that if we can’t get imports then we will set up factories and make it ourselves. Russian entrepreneurs are buying food manufacturing and packaging machinery via third party countries not involved in the ‘sanctions’. Russia also has all the German-produced equipment for manufacturing everything. As I speak to Russians on a daily basis, they are only worried about what their Ruble can buy. A lot of people bought new cars before the fall of the Ruble. White goods previously bought from Europe are now being replaced by Asian products. These products are cheaper than European items and make up for the fall in the Ruble.

I certainly will. I first saw the appointment of Scott on Bloomberg, so a quick search found the items I posted. I'm all for anti-aging supplements etc. but I am hoping that Mr Maguire has seen the information I posted and that he has further, up-to-date information that "Dr. John v Capello" of Emergent Health Group is a different Dr. Capello that lost his license as a doctor in Pennslyvania. I do not see how Scott has time to dabble in nutritional products as well as his other directorships in Healthcare Capital Partners Limited and Renal Services Ltd. Nor would I like to see the reputation of Xenetics tarnished.